Medical Syringe Manufacturing and Formulation

The contract involves the manufacturing and formulation of sterile 0.9% sodium chloride injections, supplied in 10 mL single-dose syringes. These syringes must be preservative-free and latex-free, adhering strictly to United States Pharmacopeia (USP) standards to ensure safety and quality. The manufacturing process is expected to comply with stringent pharmaceutical manufacturing practices given the sterile and preservative-free requirements. Issued by the Department of Defense under the Medical Supply Chain Pharm FSA, this subcontract aims to secure a reliable supplier for this critical medical product. The solicitation was posted on May 19, 2026, with responses due by May 26, 2026, indicating a brief turnaround time. The contract falls under NAICS code 325412, which corresponds to pharmaceutical preparation manufacturing, reflecting the specialized nature of this medical supply. The contract details do not specify a set-aside type or a particular geographical place of performance, emphasizing acceptance of qualified manufacturers that meet the technical and regulatory requirements.